Washington: A new experimental vaccine drastically extends the life of patients with the most deadly type of brain tumour, glioblastoma (GBM), according to a small-scale US study published Monday.The vaccine targets an aggressive cancer gene called EGFRvIII that fuels glioblastomas, researchers said, adding that in their study of 18 patients, survival was extended from an expected 15 months to 26 months.The study published in the Journal of Clinical Oncology also said the vaccinated patients benefited from a longer "progression-free survival period, 14.2 months, compared to 6.3 months for those who did not receive the vaccine".
Researchers found the vaccine stimulated an immune response in approximately half the patients vaccinated.Glioblastoma is the most common form of brain cancer with roughly 10,000 new cases arising in the United States each year, and the forecast for diagnosed patients is grim -- they live on average just over one year after the first diagnosis.The data suggest that these responses are linked to increased survival time, "but the numbers are so small that we can not conclude this with any degree of certainty," said co-author Amy Heimberger, of MD Anderson Cancer Centre at the University of Texas in Houston, and she urged further studies.Bureau Report
Ceasefire violation: Pak targets 2 BSF posts in J&K
DDA housing scheme cleared, over 27K flats on offer
No LoP: SC asks Modi govt to clear stand
Jaipur: Air India flight makes emergency landing due to technical fault